Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.63 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | MET | P08581 | 7/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1227537 | 0.82 | KDR (0.72) | KDRCYP3A4METCYP2D6CYP2C19 | |
| SCHEMBL5793986 | 0.81 | KDR (0.56) | KDRCYP3A4HRH3MET | |
| SCHEMBL1227536 | 0.79 | KDR (0.55) | KDRCYP3A4HRH3METCYP2D6 | |
| SCHEMBL1226468 | 0.79 | KDR (0.55) | KDRCYP3A4HRH3CYP2D6CYP2C19 | |
| SCHEMBL1226469 | 0.79 | KDR (0.61) | KDRCYP3A4MET | |
| SCHEMBL1226319 | 0.78 | KDR (0.78) | KDRCYP3A4METCYP2D6CYP2C19 | |
| SCHEMBL1226888 | 0.78 | KDR (0.65) | KDRCYP3A4MET | |
| SCHEMBL1227756 | 0.78 | KDR (1.00) | KDRCYP3A4METCYP2D6CYP2C19 | |
| SCHEMBL1227851 | 0.77 | KDR (0.63) | KDRCYP3A4MET | |
| SCHEMBL1683387 | 0.72 | SCN9A (0.43) | KDRCYP3A4METMAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280012-A2 | Pyrrolo[2,1-f][1,2,4]triazine derivatives as kinase inhibitors | Bristol-Myers Squibb Company (US) | 2011-02-02 | — | — | EP | disclosed |
| US-7820814-B2 | Inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-26 | — | — | US | disclosed |
| US-20090170853-A1 | 4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-ol; inhibit the tyrosine kinase activity of endothelial and fibroblast growth factors receptors; angiogenesis inhibitor; anticarcinogenic agent (hepatocellular cancer, colorectal cancer or non-small cell lung cancer) | BRISTOL-MYERS SQUIBB COMPANY | 2009-07-02 | — | — | US | disclosed |
| US-7521450-B2 | Inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-21 | — | — | US | disclosed |
| US-20070299075-A1 | e.g. 1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methyl-pyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-4-(aminosulfonyl)aminobutan-2-ol; inhibit the tyrosine kinase activity of endothelial and fibroblast growth factors receptors; angiogenesis inhibitor; anticarcinogenic agent | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-27 | — | — | US | disclosed |
| US-7265113-B2 | Inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-04 | — | — | US | disclosed |
| US-20050124621-A1 | Novel inhibitors of kinases | BHIDE RAJEEV S (US) | 2005-06-09 | — | — | US | disclosed |
| US-6869952-B2 | Pyrrolo[2,1-f][1,2,4]triazine inhibitors of kinases | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-03-22 | — | — | US | disclosed |
| US-20040072832-A1 | Novel inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170853-A1 | 4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-ol; inhibit the tyrosine kinase activity of endothelial and fibroblast growth factors receptors; angiogenesis inhibitor; anticarcinogenic agent (hepatocellular cancer, colorectal cancer or non-small cell lung cancer) | FGFR1, FLT1, FLT4 | KDR 6/4885CYP3A4 683/4885HRH3 3423/4885 |
| US-20040072832-A1 | Novel inhibitors of kinases | FGFR1, FLT1, FGFR2 | KDR 6/4885CYP3A4 2931/4885HRH3 3684/4885 |
| US-20050124621-A1 | Novel inhibitors of kinases | FGFR1, FLT1, FGFR2 | KDR 7/4885CYP3A4 3014/4885HRH3 4015/4885 |
| US-20070299075-A1 | e.g. 1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methyl-pyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-4-(aminosulfonyl)aminobutan-2-ol; inhibit the tyrosine kinase activity of endothelial and fibroblast growth factors receptors; angiogenesis inhibitor; anticarcinogenic agent | FGFR1, FLT1, FGFR2 | KDR 9/4885CYP3A4 2215/4885HRH3 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.